Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis

Table 4 Comparison of postoperative complications between the upfront surgery group and the neoadjuvant therapy plus surgery group

Ref.	Country	NCT number/Name	Variable	Upfront surgery	NAT plus surgery	P value
Golcher et al[7]	Germany	NCT00335543	Clavien-Dindo I-II complications	17/33 (52%)	16/33 (48%)	NM
			Clavien-Dindo III-V complications	15/33 (45%)	6/33 (18%)	NM
Versteijne et al[8]	Netherlands	PREOPANC	Postoperative complications	NM	NM	NM
Casadei et al[9]	Italy	-	Post-treatment morbidity	9/20 (45%)	10/18 (56%)	0.746
Reni et al[10]	Italy	PACT-15	Minor complications (Clavien-Dindo I–II)	21/49 (43%)	13/27 (48%)	NM
			Major complications (Clavien-Dindo III–IV)	10/49 (20%)	3/27 (11%)	NM

NAT: Neoadjuvant therapy; NM: Not mentioned.